Terms: = Prostate cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Diagnosis
114 results:
1. CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells.
Liu S; Chen X; Zhang L; Lu B
Cancer Biol Ther; 2024 Dec; 25(1):2329372. PubMed ID: 38494680
[TBL] [Abstract] [Full Text] [Related]
2. CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
[TBL] [Abstract] [Full Text] [Related]
3. Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through akt/FOXO signaling pathway.
Sun D; Guo J; Liang W; Chen Y; Wei S; Li A; Wang L; Chen X
Med Oncol; 2024 Jan; 41(2):44. PubMed ID: 38170382
[TBL] [Abstract] [Full Text] [Related]
4. Can MRI Help Inform Which Men With a History of Multifocal High-Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant prostate cancer?
Sessine MS; Radoiu CS; Qi J; Labardee C; Burks F; George AK; Lane BR; Lim K; Dabaja A; Morgan TM; Cher ML; Semerjian AM; Ginsburg KB
J Urol; 2024 Feb; 211(2):234-240. PubMed ID: 37930976
[TBL] [Abstract] [Full Text] [Related]
5. Association between prediagnostic prostate-specific antigen and prostate cancer probability in Black and non-Hispanic White men.
Lee KM; Bryant AK; Lynch JA; Robison B; Alba PR; Agiri FY; Pridgen KM; DuVall SL; Yamoah K; Garraway IP; Rose BS
Cancer; 2024 Jan; 130(2):224-231. PubMed ID: 37927109
[TBL] [Abstract] [Full Text] [Related]
6. cancer Detection Rate and Abnormal Interpretation Rate of prostate MRI in Patients With Low-Grade cancer.
Nakai H; Nagayama H; Takahashi H; Froemming AT; Kawashima A; Bolan CW; Adamo DA; Carter RE; Fazzio RT; Tsuji S; Lomas DJ; Mynderse LA; Humphreys MR; Dora C; Takahashi N
J Am Coll Radiol; 2024 Mar; 21(3):387-397. PubMed ID: 37838189
[TBL] [Abstract] [Full Text] [Related]
7. Assessing the utility of molecular diagnostic classification for cancers of unknown primary.
Moore EC; Blobe GC; DeVito NC; Hanks BA; Harrison MR; Hoimes CJ; Jia J; Morse MA; Jayaprakasan P; MacKelfresh A; Mulder H; Hockenberry AJ; Zander A; Stumpe MC; Michuda J; Beauchamp KA; Perakslis E; Taxter T; George DJ
Cancer Med; 2023 Oct; 12(19):19394-19405. PubMed ID: 37712677
[TBL] [Abstract] [Full Text] [Related]
8. Construction of lncRNA/Pseudogene-miRNA Network Based on In Silico Approaches for Glycolysis Pathway to Identify prostate Adenocarcinoma-Related Potential Biomarkers.
Khorsand M; Mostafavi-Pour Z; Tahmasebi A; Omidvar Kordshouli S; Mousavi P
Appl Biochem Biotechnol; 2024 Apr; 196(4):2332-2355. PubMed ID: 37542606
[TBL] [Abstract] [Full Text] [Related]
9. Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells.
Wang Z; Li Y; Zhao W; Jiang S; Huang Y; Hou J; Zhang X; Zhai Z; Yang C; Wang J; Zhu J; Pan J; Jiang W; Li Z; Ye M; Tan M; Jiang H; Dang Y
Signal Transduct Target Ther; 2023 May; 8(1):175. PubMed ID: 37121942
[TBL] [Abstract] [Full Text] [Related]
10. A prospective comparative study of [
Gao X; Tang Y; Chen M; Li J; Yin H; Gan Y; Zu X; Cai Y; Hu S
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2177-2187. PubMed ID: 36811661
[TBL] [Abstract] [Full Text] [Related]
11. The roles and mechanisms of circular RNAs related to mTOR in cancers.
Cao C; Wang Y; Wu X; Li Z; Guo J; Sun W
J Clin Lab Anal; 2022 Dec; 36(12):e24783. PubMed ID: 36426933
[TBL] [Abstract] [Full Text] [Related]
12. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents.
Hashemi M; Mirdamadi MSA; Talebi Y; Khaniabad N; Banaei G; Daneii P; Gholami S; Ghorbani A; Tavakolpournegari A; Farsani ZM; Zarrabi A; Nabavi N; Zandieh MA; Rashidi M; Taheriazam A; Entezari M; Khan H
Pharmacol Res; 2023 Jan; 187():106568. PubMed ID: 36423787
[TBL] [Abstract] [Full Text] [Related]
13. NOLC1 knockdown suppresses prostate cancer progressions by reducing akt phosphorylation and β-catenin accumulation.
Kim W; Yeo DY; Choi SK; Kim HY; Lee SW; Ashim J; Han JE; Yu W; Jeong H; Park JK; Park S
Biochem Biophys Res Commun; 2022 Dec; 635():99-107. PubMed ID: 36265288
[TBL] [Abstract] [Full Text] [Related]
14. RAB3D, upregulated by aryl hydrocarbon receptor (AhR), promotes the progression of prostate cancer by activating the PI3K/akt signaling pathway.
Yu J; Qi H; Wang Z; Zhang Z; Song E; Song W; An R
Cell Biol Int; 2022 Dec; 46(12):2246-2256. PubMed ID: 36153645
[TBL] [Abstract] [Full Text] [Related]
15. miR-29b Regulates Lung cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/akt Pathway.
Zhang H; Wang R; Deng Q
Comput Math Methods Med; 2022; 2022():3110330. PubMed ID: 36003920
[TBL] [Abstract] [Full Text] [Related]
16. Molecular Landscape of LncRNAs in prostate cancer: A focus on pathways and therapeutic targets for intervention.
Mirzaei S; Paskeh MDA; Okina E; Gholami MH; Hushmandi K; Hashemi M; Kalu A; Zarrabi A; Nabavi N; Rabiee N; Sharifi E; Karimi-Maleh H; Ashrafizadeh M; Kumar AP; Wang Y
J Exp Clin Cancer Res; 2022 Jul; 41(1):214. PubMed ID: 35773731
[TBL] [Abstract] [Full Text] [Related]
17. Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer.
Vanli N; Sheng J; Li S; Xu Z; Hu GF
Commun Biol; 2022 Jun; 5(1):625. PubMed ID: 35752711
[TBL] [Abstract] [Full Text] [Related]
18. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical prostate cancer Treatment: A Pan prostate cancer Group Study.
Burns D; Anokian E; Saunders EJ; Bristow RG; Fraser M; Reimand J; Schlomm T; Sauter G; Brors B; Korbel J; Weischenfeldt J; Waszak SM; Corcoran NM; Jung CH; Pope BJ; Hovens CM; Cancel-Tassin G; Cussenot O; Loda M; Sander C; Hayes VM; Dalsgaard Sorensen K; Lu YJ; Hamdy FC; Foster CS; Gnanapragasam V; Butler A; Lynch AG; Massie CE; ; Woodcock DJ; Cooper CS; Wedge DC; Brewer DS; Kote-Jarai Z; Eeles RA
Eur Urol; 2022 Aug; 82(2):201-211. PubMed ID: 35659150
[TBL] [Abstract] [Full Text] [Related]
19. race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990-2017.
Oehrlein N; Streicher SA; Kuo HC; Chaurasia A; McFadden J; Nousome D; Chen Y; Stroup SP; Musser J; Brand T; Porter C; Rosner IL; Chesnut GT; Onofaro KC; Rebbeck TR; D'Amico A; Lu-Yao G; Cullen J
Cancer Med; 2022 Nov; 11(22):4354-4365. PubMed ID: 35638719
[TBL] [Abstract] [Full Text] [Related]
20. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.
Spees LP; Dinan MA; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George DJ; Scales CD; Pritchard JE; Leapman M; Gross CP; Wheeler SB
Clin Genitourin Cancer; 2022 Oct; 20(5):e396-e405. PubMed ID: 35595633
[TBL] [Abstract] [Full Text] [Related]
[Next]
